Latest Chronic Pain News
WEDNESDAY Feb. 8 (HealthDay News) -- For people struggling with plantar fasciitis -- a painful and sometimes disabling foot condition -- a small, preliminary study suggests that a new type of therapy is more effective than standard cortisone injections in restoring mobility.
So-called "platelet-rich plasma" therapy is injected directly into the foot. It harnesses two main ingredients found in blood -- plasma and platelets -- to promote inflammation, connective-tissue growth and vascular healing. This contrasts with cortisone injections, which are designed to reduce inflammation.
"The focus here is on very difficult patients for whom well-recognized nonsurgical and surgical approaches are not effective," said study author Dr. Raymond Monto, an orthopedic surgeon with Nantucket Cottage Hospital in Nantucket, Mass. "Because while 90 percent of patients usually get better with standard treatment, about 10 percent don't.
"For these patients cortisone shots just don't help," Monto added. "The initial benefit degrades very quickly, and eventually by six months, and certainly by one year out -- you are back where you started.
"But among these sorts of patients I was very encouraged by the results with [platelet-rich plasma therapy]," Monto continued. "For most, after just one shot, we saw dramatic improvements. We're talking about the restoration of well over 90 percent of normal function lasting at least a year after treatment."
Monto was slated to present his findings Tuesday at a meeting of the American Academy of Orthopaedic Surgeons in San Francisco.
According to the American Academy of Podiatric Sports Medicine, plantar fasciitis is the most common musculoskeletal problem in the United States, typically prompted by aerobic injury or poor shoe support.
The painful condition arises from inflammation of the connective tissue running from the heel to the ball of the foot, tissue known as plantar fascia, which in turn places heavy stress on the bottom of the foot. Commonly, the condition will begin when a person feels a sharp pain in their heel as they step down after being at rest.
Standard treatment can involve a mix of nonsteroidal anti-inflammatory drugs, stretching exercises, steroid injections, rest, orthotics, improved arch support, shockwave therapy and, in some cases, surgery.
The new study focused on 36 patients (16 men and 20 women), aged 21 to 74, struggling with a severe and chronic form of plantar fasciitis. None had experienced any relief following standard nonsurgical treatments.
While the steroid group showed notable improvement within the three months following treatment, foot function started to decline by the sixth month and continued on a downward trend through to the one-year mark.
The platelet-rich plasma group experienced better initial improvement and maintained increased function throughout the following year.
"Pretty much, if the patient treated with [platelet-rich plasma therapy] saw function go up by the four-week mark, then that function was maintained," Monto said.
"But, of course, one study doesn't change patterns of treatment," he noted. "So this should be viewed as a beginning point that raises awareness of the potential of [platelet-rich plasma therapy] for this type of treatment, and hopefully initiates more research."
Dr. Howard Luks, chief of sports medicine at Westchester Medical Center and N.Y. Medical College, both in Hawthorne, N.Y., described the platelet-rich plasma therapy exploration as "worthwhile," but added that questions remain.
"The reason there has been such an interest in [platelet-rich plasma therapy] is because cortisone is degenerative," he said. "It doesn't heal tissue. It actually can damage tissue with repeated injections. So we never, as orthopedists, really had a regenerative injection option available to us."
However, platelet-rich plasma therapy "is somewhat of a controversial subject, because at this point not all [platelet-rich plasma therapy] is equal," Luks added. "Different manufacturers take a different level of the blood. Some take the white cells, some don't; some exclude platelets, some don't. So the orthopedics community at large is still sort of saying that before we adopt this widely, let's figure out exactly what we're doing and what's the best preparation. And those studies are now under way."
Unlike cortisone treatments, platelet-rich plasma therapy is not covered by insurance. Luks said that, in his experience, costs for the new treatment can range anywhere from $270 an injection to as much as $3,000.
Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.
Copyright © 2012 HealthDay. All rights reserved.